Prevalence and severity of pruritus in cutaneous T cell lymphoma

Vij, Alok; Duvic, Madeleine

doi:10.1111/j.1365-4632.2011.05188.x

Cited by 76 publications

(74 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MF and SS, which constitute 70-75% of all CTCL, are known to be associated with significant, distressing pruritus (8)(9)(10)(11)(12)(13)(14)(15)(16). To date, only a few studies have addressed the prevalence and severity of this symptom.…”

Section: Discussionmentioning

confidence: 98%

Il-31 Does not Correlate to Pruritus Related to Early Stage Cutaneous T-cell Lymphomas but is Involved in Pathogenesis of the Disease

Malek¹,

Gleń²,

Rębała³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

Mycosis fungoides (MF) and Sézary syndrome (SS) belong to the group of primary cutaneous T-cell lymphomas (CTCL). Regardless of the stage of the disease, patients with MF and SS can suffer from chronic pruritus. The aim of the study was to investigate the correlation between the interleukin 31 (IL-31) serum level, the degree of pruritus and CTCL severity; and to compare the frequency of IL-31 gene polymorphisms between patients and the control group, and between patients at different stages of the disease. Pruritus affected 67.7% of patients with MF and SS in our study. The IL-31 serum level was significantly higher in CTCL patients than in the control group but there were no positive correlation between IL-31 serum level and pruritus. A statistically significant difference in allele frequencies for IL-31 IVS2+12 gene polymorphisms between early and advanced stages was detected; GAG haplotype was more frequent and AGA was less frequent in stage IA patients compared with patients in the other stages of the disease.

show abstract

Section: Discussionmentioning

confidence: 98%

Il-31 Does not Correlate to Pruritus Related to Early Stage Cutaneous T-cell Lymphomas but is Involved in Pathogenesis of the Disease

Malek¹,

Gleń²,

Rębała³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…An estimated 66–88% of CTCL patients report experiencing pruritus with effects on quality of life [16, 17]. Reports that included Dermatology Life Quality Index (DLQI) score along with the visual analogue scale (VAS) demonstrated a high correlation between the two measures.…”

Section: Discussionmentioning

confidence: 99%

Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature

et al. 2017

View full text Add to dashboard Cite

BackgroundAprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global mediator.Case presentationsWe report a series of four patients, diagnosed with cutaneous T-cell lymphoma, who experienced full body pruritus recalcitrant to standard therapies. All patients experienced rapid symptom improvement (within days) following aprepitant treatment.ConclusionAprepitant has been shown in small studies to be efficacious for treating chronic and malignancy-associated pruritus. Prior studies have shown no change in clinical efficacy of chemotherapeutics with concurrent aprepitant administration. These cases further demonstrate that aprepitant can be considered as a therapeutic option in malignancy-associated pruritus and further support the need for larger clinical trials.

show abstract

“…For example, pruritus can interfere with sleeping patterns and impede daily activities, and patients with prolonged symptoms may require treatment for depression and insomnia [16]. Patients can experience severe pruritus regardless of disease stage, [13] although the incidence and severity of pruritus often worsens as the disease progresses [14]. In advanced CTCL, patients also commonly experience “burning pain” and sharp “pins and needles” [17].…”

Section: Overview Of Cutaneous T-cell Lymphoma and The Burden Of Prurmentioning

confidence: 99%

“…Sézary syndrome is typically associated with severe pruritus, as well as generalized erythroderma and blood involvement with or without lymphadenopathy [10]. In a retrospective analysis of patients with CTCL ( N = 551), 94% of patients with SS experienced pruritus compared with 61% with MF [14] and the mean pruritus score on a 10-point scale was 7.7 vs 3.6 for patients with SS and MF, respectively ( P < 0.001). Folliculotropic MF is an aggressive variant of MF also associated with significant pruritus [10, 15, 18].…”

Section: Overview Of Cutaneous T-cell Lymphoma and The Burden Of Prurmentioning

confidence: 99%

Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review

Field

Gao

Motwani

et al. 2016

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCL) are a heterogeneous and relatively rare group of non-Hodgkin lymphomas arising from neoplastic skin-homing memory T cells. There is no known cure for CTCL, and current treatments focus on achieving and maintaining remission, controlling symptoms, limiting toxicities and maintaining or improving quality of life. Patients with CTCL often suffer from pruritus (itching), which can be debilitating and can have a significant impact on physical well-being and quality of life. Although progress has been made towards understanding the mechanisms of pruritus, the pathophysiology of CTCL-related pruritus remains unclear. Currently, there is neither a step-wise treatment algorithm for CTCL nor a standardized approach to treating pruritus in patients with CTCL. Treatments which specifically target pruritus have been reported with varying effectiveness. However, systemic treatments that target CTCL have the potential to alleviate pruritus by treating the underlying disease. Several systemic CTCL treatments have reported anti-pruritic properties, some in both objective responders and nonresponders, but the lack of a standardized method to measure and report pruritus makes it difficult to compare the effectiveness of systemic treatments. In this review, we provide an overview of approved and investigational systemic CTCL treatments that report anti-pruritic properties. For each study, the methods used to measure and report pruritus, as well as the study design are examined so that the clinical benefits of each systemic treatment can be more readily evaluated. Funding: Financial support for medical editorial assistance and article processing charge were provided by Celgene Corporation.

show abstract

Prevalence and severity of pruritus in cutaneous T cell lymphoma

Abstract: Pruritus affects a large proportion of patients with CTCL and is significantly more severe in late- than in early-stage disease and in SS than in MF. Little information exists on the full range of the symptom burden on the patient. This aspect of patient care requires further exploration.

Cited by 76 publications

References 27 publications

Il-31 Does not Correlate to Pruritus Related to Early Stage Cutaneous T-cell Lymphomas but is Involved in Pathogenesis of the Disease

Il-31 Does not Correlate to Pruritus Related to Early Stage Cutaneous T-cell Lymphomas but is Involved in Pathogenesis of the Disease

Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature

Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review

Contact Info

Product

Resources

About